drugset / Trial / NCT00667797

Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects

NCT00667797

Phase 4 Completed 486 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupOpen-labelHealth-services research

Summary

An analysis of the costs and outcomes associated with hospitalization and treatment of Levalbuterol versus Racemic Albuterol in subjects with Asthma and COPD.

Timeline

Start
2003-03
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Levalbuterol Other / unclassified 1.25 mg Inhaled
Comparator Salbutamol Unknown 2.5 mg Inhaled